insights_auto
Outlook: 48.6% bullish·0.0% bearish
Pumunta sa pagsusurichevron_right
GILD:NASDAQ
Gilead Sciences, Inc
$156.19
arrow_downward
-0.75%(-1.18) 1D
$156.84
arrow_upward
+0.42% (+0.65)bedtimePagkalipas ng oras ng trabaho
Sarado: Okt 16, 4:00:02 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GILD...
Buksan
$157.32
Mataas
$157.58
Mababa
$155.62
Mkt. cap
193.67B
Avg. na dami
5.79M
Dami
7.77M
Dividend
2.10%
Bawat tatlong buwang dividend
$0.82
Petsa ng ex-dividend
Set 15, 2026
Mataas nang 52-wk
$160.51
Mababa nang 52-wk
$114.02
EPS
-$2.66
Beta
0.32
Mga natitirang share
1.24B
Bilang ng mga empleyado
17K
Buksan
$157.32
Mataas
$157.58
Mababa
$155.62
Mkt. cap
193.67B
Avg. na dami
5.79M
Dami
7.77M
Dividend
2.10%
Bawat tatlong buwang dividend
$0.82
Petsa ng ex-dividend
Set 15, 2026
Mataas nang 52-wk
$160.51
Mababa nang 52-wk
$114.02
EPS
-$2.66
Beta
0.32
Mga natitirang share
1.24B
Bilang ng mga empleyado
17K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
4 oras ang nakalipas
Gilead Sciences, Inc. $GILD Stake Cut by TD Waterhouse Canada Inc.
Simply Wall Street
·
16 oras ang nakalipas
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
18 oras ang nakalipas
Gilead chairman & CEO O’Day sells $2.2m in stock
MarketBeat
·
21 oras ang nakalipas
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Tungkol sa Gilead Sciences, Inc
CEODaniel O'Day
Mga Empleyado17K
ItinatagHun 22, 1987
HeadquartersFoster City, California, Estados Unidos
Sektor-
Websitegilead.com